156 related articles for article (PubMed ID: 27604276)
1. Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse.
McMahon M; Frangova TG; Henderson CJ; Wolf CR
Mol Cancer Res; 2016 Dec; 14(12):1195-1203. PubMed ID: 27604276
[TBL] [Abstract][Full Text] [Related]
2. Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase.
Campillo-Marcos I; Lazo PA
J Exp Clin Cancer Res; 2019 May; 38(1):203. PubMed ID: 31101118
[TBL] [Abstract][Full Text] [Related]
3. Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells.
Tinkum KL; Marpegan L; White LS; Sun J; Herzog ED; Piwnica-Worms D; Piwnica-Worms H
Mol Cell Biol; 2011 Sep; 31(18):3759-72. PubMed ID: 21791610
[TBL] [Abstract][Full Text] [Related]
4. Genistein, isoflavonoids in soybeans, prevents the formation of excess radiation-induced centrosomes via p21 up-regulation.
Shimada M; Kato A; Habu T; Komatsu K
Mutat Res; 2011 Nov; 716(1-2):27-32. PubMed ID: 21843532
[TBL] [Abstract][Full Text] [Related]
5. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
6. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
Wang Z; Gao J; Ohno Y; Liu H; Xu C
Cancer Chemother Pharmacol; 2020 Feb; 85(2):273-284. PubMed ID: 31907647
[TBL] [Abstract][Full Text] [Related]
8. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
9. Involvement of Oct-1 in the regulation of CDKN1A in response to clinically relevant doses of ionizing radiation.
Nenoi M; Daino K; Nakajima T; Wang B; Taki K; Kakimoto A
Biochim Biophys Acta; 2009 Mar; 1789(3):225-31. PubMed ID: 19118657
[TBL] [Abstract][Full Text] [Related]
10. p21 is Responsible for Ionizing Radiation-induced Bypass of Mitosis.
Zhang XR; Liu YA; Sun F; Li H; Lei SW; Wang JF
Biomed Environ Sci; 2016 Jul; 29(7):484-93. PubMed ID: 27554118
[TBL] [Abstract][Full Text] [Related]
11. The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Oplustil O'Connor L; Rulten SL; Cranston AN; Odedra R; Brown H; Jaspers JE; Jones L; Knights C; Evers B; Ting A; Bradbury RH; Pajic M; Rottenberg S; Jonkers J; Rudge D; Martin NM; Caldecott KW; Lau A; O'Connor MJ
Cancer Res; 2016 Oct; 76(20):6084-6094. PubMed ID: 27550455
[TBL] [Abstract][Full Text] [Related]
12. Conditional bicistronic Cre reporter line expressing both firefly luciferase and β-galactosidase.
Ishikawa TO; Herschman HR
Mol Imaging Biol; 2011 Apr; 13(2):284-92. PubMed ID: 20495880
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Norris RE; Adamson PC; Nguyen VT; Fox E
Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
[TBL] [Abstract][Full Text] [Related]
14. The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Lallo A; Frese KK; Morrow CJ; Sloane R; Gulati S; Schenk MW; Trapani F; Simms N; Galvin M; Brown S; Hodgkinson CL; Priest L; Hughes A; Lai Z; Cadogan E; Khandelwal G; Simpson KL; Miller C; Blackhall F; O'Connor MJ; Dive C
Clin Cancer Res; 2018 Oct; 24(20):5153-5164. PubMed ID: 29941481
[No Abstract] [Full Text] [Related]
15. [IL-1β inhibitor sensitizes to olaparib in homologous recombination deficiency proficient ovarian cancer cells].
Xu JF; Cen YX; Tang SS; Ren Y; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2022 Jul; 57(7):519-529. PubMed ID: 35902786
[No Abstract] [Full Text] [Related]
16. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
[TBL] [Abstract][Full Text] [Related]
17. c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage.
Udden SM; Morita-Fujimura Y; Satake M; Ikawa S
Cell Signal; 2014 Feb; 26(2):444-52. PubMed ID: 24177958
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Miyasaka A; Oda K; Ikeda Y; Wada-Hiraike O; Kashiyama T; Enomoto A; Hosoya N; Koso T; Fukuda T; Inaba K; Sone K; Uehara Y; Kurikawa R; Nagasaka K; Matsumoto Y; Arimoto T; Nakagawa S; Kuramoto H; Miyagawa K; Yano T; Kawana K; Osuga Y; Fujii T
BMC Cancer; 2014 Mar; 14():179. PubMed ID: 24625059
[TBL] [Abstract][Full Text] [Related]
19. Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity.
Sakai R; Kondo C; Oka H; Miyajima H; Kubo K; Uehara T
Toxicology; 2014 Jan; 315():8-16. PubMed ID: 24211769
[TBL] [Abstract][Full Text] [Related]
20. Firefly luciferase terminally degraded by mild heat exposure: implications for reporter assays.
Harrison EM; Garden OJ; Ross JA; Wigmore SJ
J Immunol Methods; 2006 Mar; 310(1-2):182-5. PubMed ID: 16443236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
